1620579-55-6

Basic information

• Product Name: Benzenemethanol, 3,5-difluoro-4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]-
• Synonyms: Benzenemethanol, 3,5-difluoro-4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]-;(3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)phenyl)methanol
• CAS NO: 1620579-55-6
• Molecular Formula: C₁₃H₈F₅NO₂
• Molecular Weight: 305.200136
• EINECS: -0
• Mol File: 1620579-55-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzenemethanol, 3,5-difluoro-4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 3,5-difluoro-4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]-(1620579-55-6)
• EPA Substance Registry System: Benzenemethanol, 3,5-difluoro-4-[[2-(trifluoromethyl)-4-pyridinyl]oxy]-(1620579-55-6)

Safety Data

• Hazardous Substances Data: 1620579-55-6(Hazardous Substances Data)

Upstream product

• 132123-54-7 3,4,5-trifluorobenzaldehyde 
• 170886-13-2 4-hydroxy-2-trifluoromethylpyridine 
• 204516-31-4 2-(trifluoromethyl)-4H-pyran-4-one 
• 1620579-54-5 3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzaldehyde 

Downstream Products

• 1620578-11-1 (S)-7-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy)-1,2-dimethyl-2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one 
• 1620579-10-3 (R)-7-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy)-2-methyl-2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one 

Relevant articles and documents

Tetracyclic pyrimidinone compound, preparation method, composition and application thereof

A tetracyclic pyrimidinone compound represented by a formula (I) or a pharmaceutically acceptable salt thereof has a structure represented by a formula (I), is a brand new Lp-PLA2 inhibitor, and can be used for treating neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis and thelike.

Tricyclic dihydroimidazopyrimidinone derivative, and preparation method, pharmaceutical composition and application thereof

The invention provides a compound as shown in a general formula (I), cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and an application of the compound as aLp-PLA2 inhibitor, wherein R1, R2, Rx, Ra, Q, U, X, Y, m, n and A are defined in the specification.

1,2,3,5-TETRAHYDROIMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES AND DISORDERS MEDIATED BY LP-PLA2

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases or disorders associated with the activity of Lp-PLAs